Legal Representation
Attorney
Carole R. Klein
USPTO Deadlines
Next Deadline
1102 days remaining
Section 8 (6-Year) Declaration Due (Based on registration date 2022-07-19)
Due Date
July 19, 2028
Grace Period Ends
January 19, 2029
Additional deadlines exist. Contact your attorney for complete deadline information.
Application History
22 events| Date | Code | Type | Description |
|---|---|---|---|
| Jul 19, 2022 | R.PR | A | REGISTERED-PRINCIPAL REGISTER |
| Jul 19, 2022 | NRCC | E | NOTICE OF REGISTRATION CONFIRMATION EMAILED |
| Jun 11, 2022 | SUNA | E | NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED |
| Jun 10, 2022 | CNPR | P | ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED |
| Jun 7, 2022 | AITU | A | CASE ASSIGNED TO INTENT TO USE PARALEGAL |
| Jun 7, 2022 | SUPC | I | STATEMENT OF USE PROCESSING COMPLETE |
| May 20, 2022 | EISU | I | TEAS STATEMENT OF USE RECEIVED |
| May 20, 2022 | IUAF | S | USE AMENDMENT FILED |
| May 10, 2022 | NOAM | E | NOA E-MAILED - SOU REQUIRED FROM APPLICANT |
| Mar 15, 2022 | PUBO | A | PUBLISHED FOR OPPOSITION |
| Mar 15, 2022 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| Feb 23, 2022 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| Feb 9, 2022 | CNSA | P | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Jan 28, 2022 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Jan 27, 2022 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Jan 27, 2022 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Jan 21, 2022 | DOCK | D | ASSIGNED TO EXAMINER |
| Jan 21, 2022 | CNRT | R | NON-FINAL ACTION WRITTEN |
| Jan 21, 2022 | GNRT | F | NON-FINAL ACTION E-MAILED |
| Jan 21, 2022 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| Aug 13, 2021 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| May 17, 2021 | NWAP | I | NEW APPLICATION ENTERED |
Detailed Classifications
Class 005
Pharmaceutical preparations and substances for use in the treatment of pediatric genetic disorders; pharmaceutical preparations and substances to actively fight rare, congenital, and potentially life-threatening pediatric diseases
First Use Anywhere:
Mar 15, 2022
First Use in Commerce:
Mar 15, 2022
Class 042
Pharmaceutical research, drug discovery and drug development services; medical and scientific research in the field of pediatric genetic disorders; research and development of pharmaceutical preparations for the treatment of rare, congenital, and potentially life-threatening pediatric diseases
First Use Anywhere:
Feb 10, 2022
First Use in Commerce:
Feb 10, 2022
Additional Information
Pseudo Mark
NO BIAS THERAPEUTICS
Classification
International Classes
005
042
Disclaimers
The following terms have been disclaimed and are not claimed as part of the trademark:
General Disclaimer
"THERAPEUTICS"
USPTO Documents
Loading USPTO documents...